Stryker

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Stryker 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SYK

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. 

CEO
Kevin A. Lobo
CEOKevin A. Lobo
Employees
56,000
Employees56,000
Headquarters
Portage, Michigan
HeadquartersPortage, Michigan
Founded
1941
Founded1941
Employees
56,000
Employees56,000

SYK Key Statistics

Market cap
118.92B
Market cap118.92B
Price-Earnings ratio
33.89
Price-Earnings ratio33.89
Dividend yield
1.11%
Dividend yield1.11%
Average volume
3.27M
Average volume3.27M
High today
$316.56
High today$316.56
Low today
$311.23
Low today$311.23
Open price
$315.57
Open price$315.57
Volume
1.06M
Volume1.06M
52 Week high
$389.33
52 Week high$389.33
52 Week low
$267.00
52 Week low$267.00

Stock Snapshot

As of today, Stryker(SYK) shares are valued at $312.39. The company's market cap stands at 118.92B, with a P/E ratio of 33.89 and a dividend yield of 1.11%.

On 2026-11-19, Stryker(SYK) stock moved within a range of $311.23 to $316.56. With shares now at $312.39, the stock is trading +0.4% above its intraday low and -1.3% below the session's peak.

Trading volume for Stryker(SYK) stock has reached 1.06M, versus its average volume of 3.27M.

The stock's 52-week range extends from a low of $267.00 to a high of $389.33.

The stock's 52-week range extends from a low of $267.00 to a high of $389.33.

SYK News

TipRanks 6h
Stryker price target raised to $356 from $340 at Leerink

Leerink raised the firm’s price target on Stryker (SYK) to $356 from $340 and keeps an Outperform rating on the shares. The firm has growing conviction that Med...

Simply Wall St 10h
Earnings Beat Might Change The Case For Investing In Stryker

Stryker reported third quarter adjusted EPS growth of 10.3% alongside margin gains and tight cost control, with strong contributions from Endoscopy, Medical, an...

Earnings Beat Might Change The Case For Investing In Stryker
TipRanks 3d
Stryker’s Buy Rating Holds as Growth Catalysts Support Upside Despite Price-Target Cut to $370

Stryker, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Travis Steed from Bank of America Securities maintained a Buy...

Analyst ratings

72%

of 32 ratings
Buy
71.9%
Hold
28.1%
Sell
0%

More SYK News

Simply Wall St 3d
Stryker Board Refresh And Financing Flexibility Put Valuation Back In Focus

Board appointment and fresh capital flexibility reshape Stryker story Stryker (SYK) has given investors two fresh data points to consider. A new director joins...

Stryker Board Refresh And Financing Flexibility Put Valuation Back In Focus

People also own

Based on the portfolios of people who own SYK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.